NFlection Therapeutics

NFlection Therapeutics Announces Positive Results of NFX-179 Gel in Subjects with NF1

WAYNE, PA — NFlection Therapeutics, Inc this week announced positive results from a 28-day, Phase 2a, multicenter, randomized, double-blind, parallel-group, vehicle-controlled clinical trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics …

NFlection Therapeutics Announces Positive Results of NFX-179 Gel in Subjects with NF1 Read More